Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Psyence Biomedical Ltd. (PBM:NASDAQ), powered by AI.
Psyence Biomedical Ltd. is currently trading at $11.30. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Psyence Biomedical Ltd. on Alpha Lenz.
Psyence Biomedical Ltd.'s P/E ratio is 0.0.
“Psyence Biomedical Ltd. trades at a P/E of 0.0 (undervalued) with modest ROE of -47.6%.”
Ask for details →Psyence Biomedical Ltd. is a company that specializes in the research and development of psychedelic-based therapeutics aimed at addressing mental health challenges. Its primary function is to explore the potential of psychedelics in treating conditions such as depression, PTSD, anxiety, and substance use disorders. The firm is at the forefront of innovative healthcare solutions, as it integrates cutting-edge scientific research with traditional medicinal knowledge to develop safe and effective treatment options. Notably, Psyence Biomedical collaborates with healthcare professionals, researchers, and regulatory bodies to ensure that their therapeutic offerings meet stringent safety and efficacy standards. As part of the burgeoning psychedelic industry, the company plays a significant role in potentially revolutionizing mental health care through novel approaches. Its efforts contribute to expanding the understanding of psychedelics in medicine while also addressing a growing demand for alternative and complementary mental health therapies. Psyence Biomedical's work signifies a transformative shift in the perception and utilization of psychedelics, highlighting the asset’s contribution to advancing psychiatric treatments and its growing importance in the pharmaceutical market.
“Psyence Biomedical Ltd. trades at a P/E of 0.0 (undervalued) with modest ROE of -47.6%.”
Ask for details →Psyence Biomedical Ltd. (ticker: PBM) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 12 employees. Market cap is $43,788.
The current price is $11.3 with a P/E ratio of 0.04x and P/B of 0.01x.
ROE is -47.61%.